Co-founded by acclaimed oncologist Dennis Slamon, M.D., Ph.D., of University of California at Los Angeles (UCLA) and entrepreneur and CEO David Licata, as well.
GV led Chroma Medicines Series B financing round, which the biotech will apply toward epigenetic medicines that could offer advantages over other editing technologies. Other recent financings include rounds from Cargo Therapeutics and Transcend Therapeutics.
Cargo Therapeutics is developing CAR T-cell therapies that overcome ways cancers evade currently available treatments. True to its name, the startup’s approach involves putting more cargo and more complex cargo onto engineered T cells.